Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1979-12-20
|
pubmed:abstractText |
The antidepressive effect of viloxazine (300 mg/d) was investigated during three weeks in 41 patients with depressive syndromes requiring drug-treatment against amitriptyline (150 mg/d), using a controlled double-blind design. Viloxazine differs from amitriptyline by selective inhibition of norepinephrine re-uptake, whereas amitriptyline acts also on serotonin re-uptake. Psychopathological changes were documented by means of the Hamilton Depression Rating Scale, the Bf-S (v. Zerssen), the AMDP-System, and videotaped recordings. Besides routine clinical-chemical tests, the serum concentrations of viloxazine and partly of amitriptyline were determined. Repeated EEG-recordings were evaluated by spectral analysis. The number of global responders and non-responders -- defined according to the final HDRS-scores -- was equally distributed between the two drug-groups. The AMDP-evaluation suggests that viloxazin has a somewhat more marked and more rapid effect on symptoms of retardation, whereas amitriptyline acts predominantly on depressive mood, disturbances of sleep and vital feelings. The EEG-profile of both drugs was similar to the spectral changes seen under tricyclic antidepressants, through only the viloxazine-induced changes reached statistical significance on the 10th and 20th day, the variability of the EEG-recordings being greater in the amitriptyline group. The viloxazine blood levels showed a remarkably low inter- and intraindividual variance. Steady state was reached at day 5 at the latest. Amitriptyline serum concentrations still increased between the 10th and the 21st day. The average blood concentration of viloxazine was higher in the responder- than in the non-responder-group.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0031-7098
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
321-37
|
pubmed:dateRevised |
2009-11-11
|
pubmed:meshHeading |
pubmed-meshheading:386390-Adult,
pubmed-meshheading:386390-Aged,
pubmed-meshheading:386390-Amitriptyline,
pubmed-meshheading:386390-Clinical Trials as Topic,
pubmed-meshheading:386390-Depression,
pubmed-meshheading:386390-Double-Blind Method,
pubmed-meshheading:386390-Electroencephalography,
pubmed-meshheading:386390-Female,
pubmed-meshheading:386390-Humans,
pubmed-meshheading:386390-Male,
pubmed-meshheading:386390-Middle Aged,
pubmed-meshheading:386390-Morpholines,
pubmed-meshheading:386390-Psychiatric Status Rating Scales,
pubmed-meshheading:386390-Viloxazine
|
pubmed:year |
1979
|
pubmed:articleTitle |
Clinical profile and serum concentration of viloxazine as compared to amitriptyline.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Controlled Clinical Trial
|